![Greg P. Bertenshaw](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Greg P. Bertenshaw
Directeur des opérations chez BioMarker Strategies LLC
Postes actifs de Greg P. Bertenshaw
Sociétés | Poste | Début | Fin |
---|---|---|---|
BioMarker Strategies LLC
![]() BioMarker Strategies LLC Pharmaceuticals: GenericHealth Technology BioMarker Strategies LLC develops medicines for cancer. It provides cancer diagnostics system for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. The company was founded by Scott Allocco, Kathleen Murphy and Douglas P. Clark in May 2006 and is headquartered in Rockville, MD. | Directeur des opérations | 05/06/2020 | - |
Directeur Technique/Scientifique/R&D | 01/12/2011 | - |
Historique de carrière de Greg P. Bertenshaw
Anciens postes connus de Greg P. Bertenshaw
Sociétés | Poste | Début | Fin |
---|---|---|---|
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | Directeur Technique/Scientifique/R&D | - | 07/02/2013 |
Clearant, Inc.
![]() Clearant, Inc. Pharmaceuticals: MajorHealth Technology Clearant, Inc. produces tissue allograft implants, plasma therapies, blood and recombinant products. The company was founded on April 30, 1999 and is headquartered in Orlando, FL. | Directeur/Membre du Conseil | 01/01/2002 | 02/01/2004 |
Formation de Greg P. Bertenshaw
The University of Manchester | Undergraduate Degree |
The Pennsylvania State University | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Royaume-Uni | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | Health Technology |
Clearant, Inc.
![]() Clearant, Inc. Pharmaceuticals: MajorHealth Technology Clearant, Inc. produces tissue allograft implants, plasma therapies, blood and recombinant products. The company was founded on April 30, 1999 and is headquartered in Orlando, FL. | Health Technology |
BioMarker Strategies LLC
![]() BioMarker Strategies LLC Pharmaceuticals: GenericHealth Technology BioMarker Strategies LLC develops medicines for cancer. It provides cancer diagnostics system for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. The company was founded by Scott Allocco, Kathleen Murphy and Douglas P. Clark in May 2006 and is headquartered in Rockville, MD. | Health Technology |
- Bourse
- Insiders
- Greg P. Bertenshaw
- Expérience